Casodex Articles
AstraZeneca sees strong earnings and revenue growth in2009 but a slowdown in 4th qtr
28 January 2010
AstraZeneca beats consensus forecasts with 3rd quarter 2009 profits up 22% raises forecasts
29 October 2009
Further 318 generics added to Japan's NHI list
19 May 2009
AstraZeneca's net income slips 1.6% in 4th qtr as generic competition starts to bite
9 February 2009
"30,000" fake drug packs given to NHS patients
9 February 2009
Six-month pediatric extension for AstraZeneca's Casodex
29 September 2008
Patent expiry for 2008 provides generic opportunity
14 January 2008
Call for EU review of parallel trade by EAASM
26 November 2007
UPDATE: China's fake Rx drug factories exposed, imitation Viagra "would give overdose"
1 October 2007
Bentley Pharma's bicalutamide gets Spanish OK
12 March 2007
AstraZeneca's CEO reviews Japan ops
5 March 2007
AstraZeneca's 4th-qtr profit leaps 30% but firm admits thin pipeline
13 February 2006
Strong survival benefit for AstraZeneca's Casodex
6 February 2006
Casodex' clinical and cost benefits
24 January 2005
Second FDA drug imports "blitz" finds 80% come from Canada
9 February 2004
AstraZeneca forecasts sharp rise in earnings but shares slip on mediocre Crestor sales
9 February 2004
AstraZeneca raises full-year earnings guidance
28 July 2003
Stock Commentary - Europe - 2 weeks to Dec 30
6 January 2003
AstraZeneca sales rise 6.9% in 2nd quarter
5 August 2002
FDA turns down early Casodex use
1 July 2002
Stock Commentary - Europe
1 July 2002
Stock Commentary - Europe
4 March 2002
AstraZeneca's Casodez gets fast-tracked for early prostate cancer
25 February 2002
AstraZeneca confident about overcoming loss of Prilosec revenues
11 February 2002
AstraZeneca submits sNDA to FDA for Casodex
7 January 2002
Stock Commentary - Europe
7 January 2002
AstraZeneca submits sNDA to FDA for Casodex
24 December 2001
"Robust" year for AstraZeneca
5 December 2001
MediGene files first application for Leuprogel
5 December 2001
AstraZeneca's Casodex cleared in first markets for early-stage prostate
18 September 2001
Positive Ph III data for Praecis' abarelix
6 June 2001
AstraZeneca hit by slip in Losec sales
26 April 2001
Casodex halves progression of early prostate cancer
11 April 2001
AstraZeneca files for early use of Casodex
29 March 2001
AstraZeneca issues sales and profits slowdown warning
8 February 2001
AstraZeneca sees 17% 1st qtr pretax growth
3 May 2000
AstraZeneca full-year profits up 20% as new products come good
24 February 2000
AstraZeneca unveils promising portfolio with 57 NCEs
14 December 1999
Blow to AstraZeneca's defence of Losec
13 September 1999
High-dose Casodex launched in UK
24 June 1999
Zeneca consolidates Thai business
9 March 1999
Zeneca shows confidence on Astra merger; reports good 1998 results
17 February 1999
Zeneca Receives FDA Warning Letter For Misleading Advertisments
3 December 1998
Zeneca Profits Decline, But Underlying Growth Strong
6 August 1998
UK Pharma Leaders Outline Strategy
22 June 1998
Good Earnings Growth At Zeneca Despite Strong L
5 March 1998
Zeneca's Casodex: New Labeling
29 January 1998
Pharma Sector Boosts Zeneca 1997 Performance
28 January 1998
Zeneca Allays Fears Of Near-Term Product Gap
4 December 1997
Zeneca Sees Strong Growth Against The Odds
8 August 1997
1st Approval For Novartis' Exelon; 2nd For Revasc
7 August 1997
Upbeat UK Companies At Goldman Sachs Conference
17 June 1997
Zeneca Wins Legal Challenge To Casodex
20 January 1997
Zeneca Shows Its Strength At Nine Months Stage
4 November 1996
Strong Fundamentals On Show At Zeneca
19 August 1996
"Excellent" 1st Half For Zeneca But Share Price Falls
12 August 1996
Independent Position To Be Maintained At Zeneca
18 March 1996
Zeneca's Tomudex Launched In First Market
11 March 1996
...While Court Heads Off Casodex Patent Dispute
11 March 1996
NCEs In 1995: A Good Range Of Novel Drugs
29 January 1996
Zeneca Takes Charge, But Still At Forecasts' Top-End
29 January 1996
Zeneca Reveals Typically Strong Pipeline
18 December 1995
Zeneca's Arimidex Also Backed
23 October 1995
...While Firm Gets Fast-Track Approval For Casodex In USA
16 October 1995
EUROPEAN STOCK COMMENT
2 October 1995
As Casodex Nears US Approval, Writ Issued
25 September 1995
Good Performance Forecast For Euro Drugmakers
26 June 1995
Casodex Tolerability Advantage Over Eulexin?
5 June 1995
First Launch For Zeneca's Casodex
8 May 1995
Zeneca Gets First Approval For Casodex
6 March 1995
Zeneca Files NDA For Casodex
26 September 1994
Zeneca Gets First Full Approval For Merrem
5 September 1994
ZENECA'S PIPELINE ON TARGET AS TENORMIN SLIPS
14 March 1994
CANCER MEDICINES IN DEVELOPMENT
14 June 1993
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
